The world-famous Mayo Clinic is to undertake a clinical study of Australian Medical technology company, HeraMED Limited’s (ASX:HMD) HeraBEAT Plus solution.
The HeraBEAT device safety and performance claims allow continuous and accurate measurement of foetal heart rate (FHR) and maternal heart rate (MHR) throughout the pregnancy.
CEO and Cofounder, David Groberman, said the study will evaluate the ease of use, accuracy and medical value of using the HeraBEAT smart foetal heart rate monitor at home.
The HeraBEAT is a wireless Smart Foetal Ultrasound Doppler measuring device designed to be self- administered by the expectant mother throughout the different stages of pregnancy.
The HeraBEAT device uses a smartphone-based interface, with real-time instructions for expectant mothers for determining both foetal heart rate and maternal heart rate.
Mr Groberman said the study will recruit low-risk expectant mothers from the Obstetrics and Gynaecology Department at Mayo Clinic in Rochester, Minnesota.
The overall study will be guided by an assessment of device functionality and user acceptability, as well as an evaluation of the impact of the device on expectant mother’s perception of foetal well-being, as measured by standardized surveys.
The decision to initiate a clinical study by HeraMED’s R&D collaborator is a major milestone and another significant building block in HeraMED’s US expansion strategy,” Mr Groberman concluded.
